The GMP Plasmid DNA Manufacturing Market Size is valued at 389.00 Million in 2022 and is predicted to reach 1047.14 Million by the year 2031 at a 12.1 % CAGR during the forecast period for 2023-2031.
Modern medicine heavily relies on plasmid DNA (PDNA). Plasmid DNA can be utilized either explicitly for a variety of therapeutic purposes, including gene therapy and the production of vaccine antigens, or indirectly for a broad range of research purposes. It is anticipated that the need for innovation in current manufacturing methods to meet the demand for acceptable products and their volume would offer substantial growth prospects for market players. A significant reason that propels the expansion of the GMP plasmid DNA manufacturing market is the rising number of gene therapy patients who choose to undergo the procedure.
The market for GMP plasmid DNA manufacturing will also benefit from growing government spending in the healthcare industry and an increase in older people. Plasmid DNA is in higher demand due to the need for effective illness treatment therapies. As a result, numerous businesses and research institutions are stepping up their R&D for cutting-edge treatments that target the disease's genomic origins. Due to the expanding research applications in genetic vaccination and gene therapy sectors, the market for GMP plasmid DNA manufacturing is expanding. The market is increasing favorably as more people are turning to gene therapy.
Several disorders may benefit from new potential treatments that gene therapy, a rapidly growing science, may provide. The increasing number of ties or collaborations between the different firms participating in this sector, which is anticipated to fuel the market growth, emphasizes the renewed interest in the manufacturing of plasmid deoxyribonucleic acid (DNA).
Market Segmentation:
The GMP plasmid DNA manufacturing market is segmented based on products, types and applications. Based on Products, the market is segmented into Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others.Based on types, the market is segmented as pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics. By application, the market is segmented into gene therapy, dan vaccines, immunotherapy, and others.
The Clinical Therapy Segment Is A Major Contributor To The GMP Plasmid DNA Manufacturing Market Based On The Product.
The clinical therapy category is expected to hold a major share of the global GMP plasmid DNA manufacturing market over the forecast period. Numerous plasmid DNA-based treatments are quickly moving past the clinical trial stage and will soon be available for purchase. The prevention or treatment of multiple illnesses, including cardiovascular diseases (CVDs) and cancer, including symptomatic patients, myeloid, acute ischemic, renal cell carcinoma, and coronary heart diseases, is being studied in current clinical studies based on plasmid DNA. Additionally, the role of plasmid DNA in clinical research implications for gene therapy and genetic vaccination is growing.
The Gene Therapy Segment Witnessed Growth At A Rapid Rate.
The gene therapy segment is projected to increase in the global GMP plasmid DNA manufacturing market. Gene therapy is used to alter cells and repair genetic material that is naturally flawed. Genetic problems have been successfully treated with cell and gene therapy. Gene therapies can also aid in diagnosing human viral illnesses and disorders. Additionally, the development of trustworthy and secure treatments for various ailments due to ongoing technological advancements is fueling the expansion of this market.
The North American GMP Plasmid DNA Manufacturing Market Holds A Significant Revenue Share In The Region.
The North American GMP plasmid DNA manufacturing market is expected to register the highest market share in revenue soon. Increases in cancer patients, the desire for safe and effective medical procedures, and the existence of major market participants are the main factors propelling market expansion in the North American area. The GMP plasmid DNA manufacturing market will also be boosted by expanding technical advancements in the healthcare industry and newly discovered information on the use of plasmid DNA.
In addition, Asia Pacific is projected to grow rapidly in the global GMP plasmid DNA manufacturing market. Plasmid DNA manufacturing in the region will increase due to the region's aging population, increased disease rates among patients and the government's attempt to use plasmid DNA-based products.
Competitive Landscape
Some major key players in the GMP Plasmid DNA Manufacturing Market:
- Thermos Fisher Scientific,
- Cobra Bio,
- Rescript Probe,
- Wuxi Advanced Therapies,
- Charles River,
- Weisman Biomanufacturing,
- Bioscience,
- Lake Pharma,
- Alderton,
- Kaneka Neurogenetic S.A.,
- Catalent Biologics,
- Neurogenetic,
- Nature Technology Corporation,
- Vector Builder,
- VGXI, Inc,
- Plasmid Factory,
- Delphi Genetics,
- Esko Aster, Bionian,
- Creative Biolabs,
- Vilene Biosciences,
- Patheon,
- Cognate Bio Services.
GMP Plasmid DNA Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 389.00 Million |
|
Revenue Forecast In 2031 |
USD 1047.14 Million |
|
Growth Rate CAGR |
CAGR of 12.1 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Type, Application
|
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Thermos Fisher Scientific, Cobra Bio, Rescript Probe, Wuxi Advanced Therapies, Charles River, Weisman Biomanufacturing, Bioscience, Lake Pharma, Alderton, Kaneka Neurogenetic S.A., Catalent Biologics, Neurogenetic, Nature Technology Corporation, Vector Builder, VGXI, Inc, Plasmid Factory, Delphi Genetics, Esko Aster, Bionian, Creative Biolabs, Vilene Biosciences, Patheon, Cognate Bio Services.. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
